4200 MARATHON BLVD., AUSTIN, TX
Investor Presentation
Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Reports Second Quarter 2026 Financial Results and Business Update
Plus Therapeutics Enters Equity Distribution Agreement for $17.35 Million
2026 Annual Meeting Results - Plus Therapeutics Stockholder Votes
Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Appointment of Dr. Eric J. Daniels as Chief Development Officer
Q1
Q3
Q2
Notice of Late Filing for Quarterly Report
Amended Annual Report
FY 2024
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
RW
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
S-1MEF
Correspondence
Submission Upload